01.12.2009 | Research article | Ausgabe 1/2009 Open Access

Inappropriate medication use and risk of falls – A prospective study in a large community-dwelling elderly cohort
- Zeitschrift:
- BMC Geriatrics > Ausgabe 1/2009
Electronic supplementary material
Competing interests
Authors' contributions
Background
Methods
Study population
General data
Measurement of exposure to potentially inappropriate medications
Criteria
|
|
---|---|
Indomethacin
|
Cimetidine
|
Phenylbutazone
|
Stimulant laxatives
|
Concomitant use of 2 or more NSAIDs
|
Long-acting sulfonylureas
|
Anticholinergic antidepressants
|
Methocarbamol, baclofen, tetrazepam
|
Antipsychotic drugs
|
Cerebral vasodilators (dihydroergocristine, ginkgo-biloba, pentoxifylline, ...)
|
Anticholinergic hypnotic drugs
|
Meprobamate
|
Anticholinergic antihistamines
|
Gastrointestinal antispasmodic drugs with anticholinergic properties
|
Anticholinergic muscle relaxants and antispasmodic drugs
|
Antiemetics, cough suppressants, nasal decongestants, or antidrowsiness drugs with anticholinergic properties
|
Concomitant use of drugs with anticholinergic properties
|
Dipyridamole
|
Long-acting benzodiazepines (half-life ≥ 20 h)
|
Nitrofurantoin
|
Centrally acting antihypertensives
|
Concomitant use of 2 or more psychotropic drugs from the same therapeutic class
|
Short-acting calcium-channel blockers
|
Concomitant use of anticholinesterase drugs and drugs with anticholinergic properties
|
Reserpine
|
Barbiturates (except phenobarbital)
|
Disopyramide
|
Doxazosin
|
Ticlopidine
|
Falls
Data analysis
Results
Characteristics of the study population
Variable n (%)
|
No fall (n = 3670)
|
One fall (n = 1291)
|
≥ 2 falls
(n = 1382)
|
crude p-value
|
---|---|---|---|---|
Women
|
1922 (52)
|
833 (65)
|
987 (71)
|
<.001
|
Age (years)
|
||||
<75
|
2364 (64)
|
733 (57)
|
707 (51)
|
<.001
|
75–79
|
886 (24)
|
364 (28)
|
419 (30)
|
|
≥80
|
420 (12)
|
194 (15)
|
256 (19)
|
|
Living alone
|
1107 (30)
|
494 (38)
|
574 (41)
|
<.001
|
Years of schooling
|
||||
≤5
|
1204 (33)
|
420 (33)
|
474 (34)
|
.86
|
6–9
|
1086 (30)
|
378 (29)
|
400 (29)
|
|
10–12
|
479 (13)
|
183 (14)
|
185 (14)
|
|
≥13
|
901 (24)
|
308 (24)
|
322 (23)
|
|
Body Mass Index
|
||||
<25
|
1701 (46)
|
641 (50)
|
648 (48)
|
.09
|
25–29
|
1489 (41)
|
478 (37)
|
524 (38)
|
|
≥30
|
464 (13)
|
166 (13)
|
196 (14)
|
|
Depressive symptoms*
|
369 (10)
|
176 (14)
|
201 (15)
|
<.001
|
MMSE ≥ 28†
|
2117 (58)
|
748 (58)
|
762 (55)
|
.24
|
Impaired mobility‡
|
1351 (37)
|
579 (46)
|
724 (53)
|
<.001
|
Diurnal drowsiness
|
554 (16)
|
206 (17)
|
259 (21)
|
.001
|
Number of drugs used ≥ 5 §
|
1140 (31)
|
459 (36)
|
573 (41)
|
<.001
|
At least one inappropriate medication
|
1092 (30)
|
408 (32)
|
504 (36)
|
<.001
|
Association between baseline use of inappropriate medication during the 4 years and risk of falls
≤ 1 fall
|
≥ 2 falls
|
|||||
---|---|---|---|---|---|---|
Medication n (%)
|
(N = 4961)
|
(N = 1382)
|
RR (95% CI)
|
crude P-value
|
RR (95% CI)*
|
P-value*
|
Inappropriate medication, full list
|
1500 (30.2)
|
504 (36.5)
|
||||
Inappropriate medication, excluding cerebral vasodilators
|
924 (18.6)
|
315 (22.8)
|
1.27 (1.12–1.43)
|
<.001
|
1.05 (0.92–1.20)
|
.47
|
Long-acting benzodiazepines
|
351 (7.1)
|
144 (10.4)
|
1.46 (1.23–1.74)
|
<.001
|
1.20 (1.00–1.43)
|
.048
|
Inappropriate psychotropic drugs
|
108 (2.2)
|
47 (3.4)
|
1.60 (1.20–2.14)
|
.002
|
1.31 (0.97–1.76)
|
.08
|
Inappropriate medication with anticholinergic properties
|
223 (4.5)
|
92 (6.7)
|
1.50 (1.21–1.85)
|
<.001
|
1.18 (0.96–1.47)
|
.13
|
Short- or intermediate-half-life benzodiazepines
|
568 (11.5)
|
206 (14.9)
|
1.31 (1.13–1.51)
|
<.001
|
0.99 (0.85–1.16)
|
.89
|
≤ 1 fall
|
≥ 2 falls
|
|||||
---|---|---|---|---|---|---|
Medication n (%)
|
(N = 4961)
|
(N = 1382)
|
OR (95% CI)
|
crude P-Value
|
OR (95% CI)*†
|
P-Value†
|
Inappropriate medication full list
|
||||||
Occasional user‡
|
809 (16)
|
277 (20)
|
1.48 (1.26–1.74)
|
<.001
|
1.23 (1.04–1.45)
|
.016
|
Regular user §
|
1389 (28)
|
465 (34)
|
1.45 (1.26–1.66)
|
<.001
|
1.08 (0.94–1.25)
|
.29
|
Inappropriate medication without cerebral vasodilators
|
||||||
Occasional user
|
704 (14)
|
239 (17)
|
1.38 (1.17–1.63)
|
<.001
|
1.22 (1.02–1.45)
|
.030
|
Regular user
|
826 (17)
|
300 (22)
|
1.48 (1.27–1.72)
|
<.001
|
1.19 (1.00–1.41)
|
.049
|
Long-acting benzodiazepines
|
||||||
Occasional user
|
286 (9)
|
117 (13)
|
1.58 (1.26–1.98)
|
<.001
|
1.40 (1.10–1.79)
|
.006
|
Regular user
|
316 (9)
|
135 (15)
|
1.65 (1.33–2.04)
|
<.001
|
1.41 (1.12–1.79)
|
.004
|
Inappropriate psychotropic drugs
|
||||||
Occasional user
|
102 (2)
|
37 (3)
|
1.33 (0.91–1.95)
|
.14
|
1.17 (0.74–1.83)
|
.50
|
Regular user
|
74 (1)
|
39 (3)
|
1.93 (1.30–2.86)
|
.001
|
1.74 (1.14–2.66)
|
.010
|
Inappropriate medication with anticholinergic properties
|
||||||
Occasional user
|
264 (5)
|
91 (7)
|
1.29 (1.01–1.65)
|
.042
|
1.21 (0.93–1.58)
|
.15
|
Regular user
|
172 (3)
|
84 (6)
|
1.83 (1.40–2.40)
|
<.001
|
1.57 (1.18–2.10)
|
.002
|
Short- or intermediate-half-life benzodiazepines
|
||||||
Occasional user
|
429 (9)
|
151 (11)
|
1.34 (1.10–1.63)
|
.004
|
1.20 (0.96–1.49)
|
.11
|
Regular user
|
441 (9)
|
153 (11)
|
1.32 (1.08–1.60)
|
.006
|
1.05 (0.83–1.32)
|
.69
|